SonALAsense

SonALAsense’s ALA sonodynamic therapy (SDT) is well differentiated from the use of other forms of therapy which have been used for GBM or rGBM. Our use of a MRI-guided focused ultrasound device with ALA is a true drug-device combination, where both the drug and the device are required for a therapeutic effect. SDT has a well elucidated mechanism of action (creation of reactive oxygen species). SDT is non-invasive and is likely to be safe and well tolerated (as shown by its individual FDA-approved components). In terms of overall survival of rGBM patients, the efficacy of SDT is likely to extend survival due to the selective uptake of ALA by GBM cells and SDT’s unique ability to both immediately kill GBM cells at the beam focus, and to trigger the process of GBM programmed cell death (apoptosis) at areas around the focus.